LUMINARAHot Line 6Heart Failure
LUMINARA
A once-daily oral relaxin agonist (AZD5462) in patients with heart failure
Presenting authorJames JanuzziHeart Failure / Cardiomyopathy · Harvard UniversityJames L. Januzzi, MD is the Hutter Family Professor of Medicine at Harvard Medical School and a staff cardiologist at Massachusetts General Hospital. He has been on the MGH Cardiology Division faculty since 2000, with a focus on heart failure, chronic coronary artery disease, and cardiac biomarker testing. He has authored or co-authored numerous publications including heart failure guidelines and trials on empagliflozin.
Overview
A once-daily oral relaxin agonist (AZD5462) in patients with heart failure
Key result
The once-daily oral relaxin agonist AZD5462 is being evaluated in patients with heart failure, with late-breaking clinical trial results currently pending.
Discussion
Expert reaction lands here the moment LUMINARA reports.
Main Result
Absolute Event Rate: 0% vs 0%